Inovio Pharmaceuticals, Inc. (INO)
Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Inovio Pharmaceuticals NASDAQ: INO shareholders approved all proposals presented at the company's 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the year ending Dec. 31, 2026.
Inovio: All Eyes On INO-3107 As Binary FDA Decision Looms
Inovio Pharmaceuticals remains a high-risk, event-driven play, with the investment case dominated by the binary FDA decision for INO-3107 in October. Cost discipline has improved, with operating expenses down to $21.9M and cash projected to fund operations into 1Q27, reducing near-term dilution risk. INO-3107 offers a differentiated, patient-friendly profile versus PAPZIMEOS, targeting a potentially larger-than-expected RRP population and non-responders.
Inovio (INO) Loses 32.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Inovio (INO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Inovio (INO) Looks Ripe for Bottom Fishing
Inovio (INO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inovio Stock Up On Earnings, Pipeline Progress
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher on Friday morning after the company reported fourth-quarter results that topped Wall Street's loss estimate and highlighted progress on its lead DNA medicine candidate. Here's what investors need to know.
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107
I believe Inovio Pharmaceuticals' upside rests almost entirely on INO-3107. The FDA set a standard-review PDUFA for October 30, 2026. INO-3107 targets HPV-6/11 RRP, aiming to reduce repeat surgeries by inducing HPV-specific T-cell responses and addressing the disease's underlying causes. But the FDA questioned INO-3107's accelerated approval. I think this increases the risk of longer timelines with larger confirmatory requirements.
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inovio (INO) Upgraded to Buy: Here's Why
Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
